SC
OCUL icon

Stempoint Capital’s Ocular Therapeutix OCUL Stock Holding History

Stempoint Capital’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-522,693
Closed -$6.35M – 108
2025
Q4 		$6.35M Buy
522,693
+163,223
+45% +$1.98M 1.09% 30
2025
Q3 		$4.2M Buy
+359,470
New +$4.3M 0.84% 32
2025
Q2 		– Sell
-124,523
Closed -$913K – 73
2025
Q1 		$913K Buy
+124,523
New +$957K 0.29% 44
2024
Q1 		– Sell
-279,648
Closed -$1.25M – 87
2023
Q4 		$1.25M Buy
+279,648
New +$827K 0.33% 54

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Stempoint Capital's OCUL Position: Q1 2026 in Review

Stempoint Capital sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 522,693 shares — an estimated $6.35M sold.

Stempoint Capital first reported a position in OCUL in Q4 2023 and held it in 4 quarters. The position peaked at $6.35M in Q4 2025. 271 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Stempoint Capital reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
  • Stempoint Capital sold 522,693 Ocular Therapeutix shares in Q1 2026, an estimated $6.35M.
  • Stempoint Capital first reported a position in Ocular Therapeutix in Q4 2023 and held it in 4 quarters.
  • Stempoint Capital's Ocular Therapeutix position peaked at $6.35M in Q4 2025.
  • 271 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.